The cost-effectiveness of omega-3 supplements for prevention of secondary coronary events.

Jordana K. Schmier, Nancy J. Rachman, Michael Halpern

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

PURPOSE: To project the clinical and economic benefits of omega-3 supplements for prevention of secondary (repeat) cardiovascular events in U.S. males. DESIGN: Decision-analytic model. METHODOLOGY: Model clinical probabilities (rates of fatal myocardial infarction [MI] and cardiovascular death) were based on published trials. Costs were derived from standard U.S. sources. Outcomes include deaths delayed, cost per death delayed, fatal MIs avoided, and cost per fatal MI avoided. Costs, outcomes, and cost-effectiveness were determined for the initial year and over a 42-month model period. Sensitivity analyses were conducted to evaluate the robustness of key model assumptions. PRINCIPAL FINDINGS: According to the model, the use of omega-3 supplements results in fewer fatal MIs and fewer cardiovascular deaths in the short-term (1 year) and longterm (42-month) analyses. When including only direct medical treatment costs for fatal MIs, omega-3 supplementation is cost-effective compared to no supplementation. In terms of total costs (medical costs and decreased productivity), supplementation is cost-saving, providing better outcomes and lower/fewer costs. Supplementation remained cost-effective in all sensitivity analyses. CONCLUSION: Under a variety of scenarios, omega-3 supplements are likely to improve health and lower total costs. Despite model limitations, omega-3 supplementation should be considered an important and cost-effective option for prevention of secondary cardiovascular events.

Original languageEnglish (US)
Pages (from-to)43-50
Number of pages8
JournalManaged care (Langhorne, Pa.)
Volume15
Issue number4
StatePublished - Apr 2006
Externally publishedYes

Fingerprint

Secondary Prevention
Cost-Benefit Analysis
Costs and Cost Analysis
Myocardial Infarction
Health Care Costs
Economics

Cite this

The cost-effectiveness of omega-3 supplements for prevention of secondary coronary events. / Schmier, Jordana K.; Rachman, Nancy J.; Halpern, Michael.

In: Managed care (Langhorne, Pa.), Vol. 15, No. 4, 04.2006, p. 43-50.

Research output: Contribution to journalArticle

@article{c48249aa364c4c12a8f26312ad2bfdb3,
title = "The cost-effectiveness of omega-3 supplements for prevention of secondary coronary events.",
abstract = "PURPOSE: To project the clinical and economic benefits of omega-3 supplements for prevention of secondary (repeat) cardiovascular events in U.S. males. DESIGN: Decision-analytic model. METHODOLOGY: Model clinical probabilities (rates of fatal myocardial infarction [MI] and cardiovascular death) were based on published trials. Costs were derived from standard U.S. sources. Outcomes include deaths delayed, cost per death delayed, fatal MIs avoided, and cost per fatal MI avoided. Costs, outcomes, and cost-effectiveness were determined for the initial year and over a 42-month model period. Sensitivity analyses were conducted to evaluate the robustness of key model assumptions. PRINCIPAL FINDINGS: According to the model, the use of omega-3 supplements results in fewer fatal MIs and fewer cardiovascular deaths in the short-term (1 year) and longterm (42-month) analyses. When including only direct medical treatment costs for fatal MIs, omega-3 supplementation is cost-effective compared to no supplementation. In terms of total costs (medical costs and decreased productivity), supplementation is cost-saving, providing better outcomes and lower/fewer costs. Supplementation remained cost-effective in all sensitivity analyses. CONCLUSION: Under a variety of scenarios, omega-3 supplements are likely to improve health and lower total costs. Despite model limitations, omega-3 supplementation should be considered an important and cost-effective option for prevention of secondary cardiovascular events.",
author = "Schmier, {Jordana K.} and Rachman, {Nancy J.} and Michael Halpern",
year = "2006",
month = "4",
language = "English (US)",
volume = "15",
pages = "43--50",
journal = "Managed Care",
issn = "1062-3388",
publisher = "MediMedia USA Inc.",
number = "4",

}

TY - JOUR

T1 - The cost-effectiveness of omega-3 supplements for prevention of secondary coronary events.

AU - Schmier, Jordana K.

AU - Rachman, Nancy J.

AU - Halpern, Michael

PY - 2006/4

Y1 - 2006/4

N2 - PURPOSE: To project the clinical and economic benefits of omega-3 supplements for prevention of secondary (repeat) cardiovascular events in U.S. males. DESIGN: Decision-analytic model. METHODOLOGY: Model clinical probabilities (rates of fatal myocardial infarction [MI] and cardiovascular death) were based on published trials. Costs were derived from standard U.S. sources. Outcomes include deaths delayed, cost per death delayed, fatal MIs avoided, and cost per fatal MI avoided. Costs, outcomes, and cost-effectiveness were determined for the initial year and over a 42-month model period. Sensitivity analyses were conducted to evaluate the robustness of key model assumptions. PRINCIPAL FINDINGS: According to the model, the use of omega-3 supplements results in fewer fatal MIs and fewer cardiovascular deaths in the short-term (1 year) and longterm (42-month) analyses. When including only direct medical treatment costs for fatal MIs, omega-3 supplementation is cost-effective compared to no supplementation. In terms of total costs (medical costs and decreased productivity), supplementation is cost-saving, providing better outcomes and lower/fewer costs. Supplementation remained cost-effective in all sensitivity analyses. CONCLUSION: Under a variety of scenarios, omega-3 supplements are likely to improve health and lower total costs. Despite model limitations, omega-3 supplementation should be considered an important and cost-effective option for prevention of secondary cardiovascular events.

AB - PURPOSE: To project the clinical and economic benefits of omega-3 supplements for prevention of secondary (repeat) cardiovascular events in U.S. males. DESIGN: Decision-analytic model. METHODOLOGY: Model clinical probabilities (rates of fatal myocardial infarction [MI] and cardiovascular death) were based on published trials. Costs were derived from standard U.S. sources. Outcomes include deaths delayed, cost per death delayed, fatal MIs avoided, and cost per fatal MI avoided. Costs, outcomes, and cost-effectiveness were determined for the initial year and over a 42-month model period. Sensitivity analyses were conducted to evaluate the robustness of key model assumptions. PRINCIPAL FINDINGS: According to the model, the use of omega-3 supplements results in fewer fatal MIs and fewer cardiovascular deaths in the short-term (1 year) and longterm (42-month) analyses. When including only direct medical treatment costs for fatal MIs, omega-3 supplementation is cost-effective compared to no supplementation. In terms of total costs (medical costs and decreased productivity), supplementation is cost-saving, providing better outcomes and lower/fewer costs. Supplementation remained cost-effective in all sensitivity analyses. CONCLUSION: Under a variety of scenarios, omega-3 supplements are likely to improve health and lower total costs. Despite model limitations, omega-3 supplementation should be considered an important and cost-effective option for prevention of secondary cardiovascular events.

UR - http://www.scopus.com/inward/record.url?scp=33745153404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745153404&partnerID=8YFLogxK

M3 - Article

C2 - 16686171

AN - SCOPUS:33745153404

VL - 15

SP - 43

EP - 50

JO - Managed Care

JF - Managed Care

SN - 1062-3388

IS - 4

ER -